



Current Advances in Clinical Genomics and Treatment of Urothelial Carcinoma

Guest Editor:

Dr. Panagiotis Vlachostergios

Division of Hematology and
Medical Oncology, Weill Cornell
Medicine, New York, NY, USA

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editor

Dear Colleagues,

Immense progress in large-scale genomics projects is transforming the therapeutic landscape of various cancers. Urothelial carcinoma is a common, potentially lethal malignancy, particularly in the advanced stage. Immune checkpoint inhibitors, antibody drug conjugates, and novel targeted agents have become part of the treatment armamentarium for urothelial carcinoma. An important challenge for clinicians is how to best utilize genomic approaches to predict treatment responses and identify patients who can derive a preferential benefit from these therapeutic options. This Special Issue aims at providing an update on recent advances in the molecular landscape of UC and how genomic alterations in key signaling pathways might serve in biomarker development, drug development, and prediction of patient outcomes.

Dr. Panagiotis J. Vlachostergios

Guest Editor

